Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 355 entries
Sorted by: Best Match Show Resources per page
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.

Breast care (Basel, Switzerland)

Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M.
PMID: 26557827
Breast Care (Basel). 2015 Jul;10(3):211-9. doi: 10.1159/000433590. Epub 2015 Jun 23.

The key topics of this year's 14th St. Gallen Consensus Conference on the diagnosis and therapy of primary breast cancer were again questions about breast surgery and axillary surgery, radio-oncology and systemic therapy options in consideration of tumor biology,...

Cite
Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). 2015;10(3):211-9doi: 10.1159/000433590.
Jackisch, C., Harbeck, N., Huober, J., von Minckwitz, G., Gerber, B., Kreipe, H. H., Liedtke, C., Marschner, N., Möbus, V., Scheithauer, H., Schneeweiss, A., Thomssen, C., Loibl, S., Beckmann, M. W., Blohmer, J. U., Costa, S. D., Decker, T., Diel, I., Fasching, P. A., Fehm, T., Janni, W., Lück, H. J., Maass, N., Scharl, A., & Untch, M. (2015). 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast care (Basel, Switzerland), 10(3), 211-9. https://doi.org/10.1159/000433590
Jackisch, Christian, et al. "14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts." Breast care (Basel, Switzerland) vol. 10,3 (2015): 211-9. doi: https://doi.org/10.1159/000433590
Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). 2015 Jul;10(3):211-9. doi: 10.1159/000433590. Epub 2015 Jun 23. PMID: 26557827; PMCID: PMC4569213.
Copy Download .nbib Format: NLM
Hepatocyte Paraffin 1 Immunoreactivity in Early Colon Carcinogenesis.

Gastroenterology research

Nemolato S, Ravarino A, Fanni D, Coni P, Di Felice E, Senes G, Faa G.
PMID: 27956971
Gastroenterology Res. 2009 Oct;2(5):277-281. doi: 10.4021/gr2009.10.1313. Epub 2009 Sep 20.

BACKGROUND: This study was aimed at evaluating the correlation between Hepatocyte paraffin 1 (Hep par 1) and colorectal cancer.METHODS: To this end, 50 intestinal biopsies were analyzed including 10 colorectal polyps with low grade dysplasia, 10 with high grade...

Cite
Nemolato S, Ravarino A, Fanni D, et al. Hepatocyte Paraffin 1 Immunoreactivity in Early Colon Carcinogenesis. Gastroenterology Res. 2009;2(5):277-281doi: 10.4021/gr2009.10.1313.
Nemolato, S., Ravarino, A., Fanni, D., Coni, P., Di Felice, E., Senes, G., & Faa, G. (2009). Hepatocyte Paraffin 1 Immunoreactivity in Early Colon Carcinogenesis. Gastroenterology research, 2(5), 277-281. https://doi.org/10.4021/gr2009.10.1313
Nemolato, Sonia, et al. "Hepatocyte Paraffin 1 Immunoreactivity in Early Colon Carcinogenesis." Gastroenterology research vol. 2,5 (2009): 277-281. doi: https://doi.org/10.4021/gr2009.10.1313
Nemolato S, Ravarino A, Fanni D, Coni P, Di Felice E, Senes G, Faa G. Hepatocyte Paraffin 1 Immunoreactivity in Early Colon Carcinogenesis. Gastroenterology Res. 2009 Oct;2(5):277-281. doi: 10.4021/gr2009.10.1313. Epub 2009 Sep 20. PMID: 27956971; PMCID: PMC5139774.
Copy Download .nbib Format: NLM
Clinical validation of genetic variants associated with .

Oncotarget

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.
PMID: 29100455
Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS...

Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Geburtshilfe und Frauenheilkunde

Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
PMID: 29576630
Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.

The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes...

Cite
Schneeweiss A, Lux MP, Janni W, et al. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018;78(3):246-259doi: 10.1055/s-0044-101614.
Schneeweiss, A., Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F. A., Overkamp, F., Kolberg, H. C., Hadji, P., Tesch, H., Wöckel, A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wallwiener, D., Brucker, S. Y., Schütz, F., Fasching, P. A., & Fehm, T. N. (2018). Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe und Frauenheilkunde, 78(3), 246-259. https://doi.org/10.1055/s-0044-101614
Schneeweiss, Andreas, et al. "Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention." Geburtshilfe und Frauenheilkunde vol. 78,3 (2018): 246-259. doi: https://doi.org/10.1055/s-0044-101614
Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21. PMID: 29576630; PMCID: PMC5862553.
Copy Download .nbib Format: NLM
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

Geburtshilfe und Frauenheilkunde

Fasching PA, Fehm T, Kellner S, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Würstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauß T, Thomssen C, Kümmel S, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Wallwiener D, Grischke EM, Beckmann MW, Brucker SY.
PMID: 25568468
Geburtshilfe Frauenheilkd. 2014 Dec;74(12):1137-1143. doi: 10.1055/s-0034-1383401.

No abstract available.

Cite
Fasching PA, Fehm T, Kellner S, et al. Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd. 2014;74(12):1137-1143doi: 10.1055/s-0034-1383401.
Fasching, P. A., Fehm, T., Kellner, S., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. C., Guggenberger, M., Warm, M., Harbeck, N., Würstlein, R., Deuker, J. U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. W., Breitbach, G. P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesslet, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kühn, T., Krauß, T., Thomssen, C., Kümmel, S., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Hadji, P., Wallwiener, D., Grischke, E. M., Beckmann, M. W., & Brucker, S. Y. (2014). Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe und Frauenheilkunde, 74(12), 1137-1143. https://doi.org/10.1055/s-0034-1383401
Fasching, P A, et al. "Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study." Geburtshilfe und Frauenheilkunde vol. 74,12 (2014): 1137-1143. doi: https://doi.org/10.1055/s-0034-1383401
Fasching PA, Fehm T, Kellner S, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Würstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauß T, Thomssen C, Kümmel S, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Wallwiener D, Grischke EM, Beckmann MW, Brucker SY. Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd. 2014 Dec;74(12):1137-1143. doi: 10.1055/s-0034-1383401. PMID: 25568468; PMCID: PMC4275317.
Copy Download .nbib Format: NLM
Synthesis of asymmetrically substituted terpyridines by palladium-catalyzed direct C-H arylation of pyridine N-oxides.

Chemistry (Weinheim an der Bergstrasse, Germany)

Duric S, Sypaseuth FD, Hoof S, Svensson E, Tzschucke CC.
PMID: 24227705
Chemistry. 2013 Dec 16;19(51):17456-63. doi: 10.1002/chem.201302118. Epub 2013 Nov 13.

The synthesis of asymmetrically substituted 2,2':6',2''-terpyridines is reported. First, palladium-catalyzed C-H arylation of pyridine N-oxides with substituted bromopyridines gave 2,2'-bipyridine N-oxides, which were further arylated in a second step to form 2,2':6',2''-terpyridine N-oxides. Yields of up to 77% were...

Cite
Duric S, Sypaseuth FD, Hoof S, et al. Synthesis of asymmetrically substituted terpyridines by palladium-catalyzed direct C-H arylation of pyridine N-oxides. Chemistry. 2013;19(51):17456-63doi: 10.1002/chem.201302118.
Duric, S., Sypaseuth, F. D., Hoof, S., Svensson, E., & Tzschucke, C. C. (2013). Synthesis of asymmetrically substituted terpyridines by palladium-catalyzed direct C-H arylation of pyridine N-oxides. Chemistry (Weinheim an der Bergstrasse, Germany), 19(51), 17456-63. https://doi.org/10.1002/chem.201302118
Duric, Sasa, et al. "Synthesis of asymmetrically substituted terpyridines by palladium-catalyzed direct C-H arylation of pyridine N-oxides." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 19,51 (2013): 17456-63. doi: https://doi.org/10.1002/chem.201302118
Duric S, Sypaseuth FD, Hoof S, Svensson E, Tzschucke CC. Synthesis of asymmetrically substituted terpyridines by palladium-catalyzed direct C-H arylation of pyridine N-oxides. Chemistry. 2013 Dec 16;19(51):17456-63. doi: 10.1002/chem.201302118. Epub 2013 Nov 13. PMID: 24227705.
Copy Download .nbib Format: NLM
Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?.

Breast care (Basel, Switzerland)

Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B.
PMID: 24803882
Breast Care (Basel). 2014 Feb;9(1):16-21. doi: 10.1159/000360438.

In clinical practice imaging technologies such as computed tomography (CT), positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) are well-established methods for monitoring metastatic breast cancer (MBC) patients and for assessing therapeutic efficacy. However, several weeks of treatment...

Cite
Alunni-Fabbroni M, Müller V, Fehm T, et al. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast Care (Basel). 2014;9(1):16-21doi: 10.1159/000360438.
Alunni-Fabbroni, M., Müller, V., Fehm, T., Janni, W., & Rack, B. (2014). Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast care (Basel, Switzerland), 9(1), 16-21. https://doi.org/10.1159/000360438
Alunni-Fabbroni, Marianna, et al. "Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?." Breast care (Basel, Switzerland) vol. 9,1 (2014): 16-21. doi: https://doi.org/10.1159/000360438
Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast Care (Basel). 2014 Feb;9(1):16-21. doi: 10.1159/000360438. PMID: 24803882; PMCID: PMC3995372.
Copy Download .nbib Format: NLM
Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment.

World journal of nephrology

Jensen JM, Mose FH, Kulik AE, Bech JN, Fenton RA, Pedersen EB.
PMID: 26167467
World J Nephrol. 2015 Jul 06;4(3):423-37. doi: 10.5527/wjn.v4.i3.423.

AIM: To quantify changes in urinary excretion of aquaporin2 water channels (u-AQP2), the sodium-potassium-chloride co-transporter (u-NKCC2) and the epithelial sodium channels (u-ENaC) during treatment with bendroflumethiazide (BFTZ), amiloride and placebo.METHODS: In a randomized, double-blinded, placebo-controlled, 3-way crossover study we...

Cite
Jensen JM, Mose FH, Kulik AE, et al. Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment. World J Nephrol. 2015;4(3):423-37doi: 10.5527/wjn.v4.i3.423.
Jensen, J. M., Mose, F. H., Kulik, A. E., Bech, J. N., Fenton, R. A., & Pedersen, E. B. (2015). Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment. World journal of nephrology, 4(3), 423-37. https://doi.org/10.5527/wjn.v4.i3.423
Jensen, Janni M, et al. "Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment." World journal of nephrology vol. 4,3 (2015): 423-37. doi: https://doi.org/10.5527/wjn.v4.i3.423
Jensen JM, Mose FH, Kulik AE, Bech JN, Fenton RA, Pedersen EB. Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment. World J Nephrol. 2015 Jul 06;4(3):423-37. doi: 10.5527/wjn.v4.i3.423. PMID: 26167467; PMCID: PMC4491934.
Copy Download .nbib Format: NLM
Olfaction: An Overlooked Sensory Modality in Applied Ethology and Animal Welfare.

Frontiers in veterinary science

Nielsen BL, Jezierski T, Bolhuis JE, Amo L, Rosell F, Oostindjer M, Christensen JW, McKeegan D, Wells DL, Hepper P.
PMID: 26664995
Front Vet Sci. 2015 Dec 03;2:69. doi: 10.3389/fvets.2015.00069. eCollection 2015.

No abstract available.

Cite
Nielsen BL, Jezierski T, Bolhuis JE, et al. Olfaction: An Overlooked Sensory Modality in Applied Ethology and Animal Welfare. Front Vet Sci. 2015;2:69doi: 10.3389/fvets.2015.00069.
Nielsen, B. L., Jezierski, T., Bolhuis, J. E., Amo, L., Rosell, F., Oostindjer, M., Christensen, J. W., McKeegan, D., Wells, D. L., & Hepper, P. (2015). Olfaction: An Overlooked Sensory Modality in Applied Ethology and Animal Welfare. Frontiers in veterinary science, 269. https://doi.org/10.3389/fvets.2015.00069
Nielsen, Birte L, et al. "Olfaction: An Overlooked Sensory Modality in Applied Ethology and Animal Welfare." Frontiers in veterinary science vol. 2 (2015): 69. doi: https://doi.org/10.3389/fvets.2015.00069
Nielsen BL, Jezierski T, Bolhuis JE, Amo L, Rosell F, Oostindjer M, Christensen JW, McKeegan D, Wells DL, Hepper P. Olfaction: An Overlooked Sensory Modality in Applied Ethology and Animal Welfare. Front Vet Sci. 2015 Dec 03;2:69. doi: 10.3389/fvets.2015.00069. eCollection 2015. PMID: 26664995; PMCID: PMC4672279.
Copy Download .nbib Format: NLM
A bibenzimidazole-containing ruthenium(II) complex acting as a cation-driven molecular switch.

Inorganic chemistry

Rau S, Büttner T, Temme C, Ruben M, Görls H, Walther D, Duati M, Fanni S, Vos JG.
PMID: 12526478
Inorg Chem. 2000 Apr 03;39(7):1621-4. doi: 10.1021/ic991225h.

No abstract available.

Cite
Rau S, Büttner T, Temme C, et al. A bibenzimidazole-containing ruthenium(II) complex acting as a cation-driven molecular switch. Inorg Chem. 2000;39(7):1621-4doi: 10.1021/ic991225h.
Rau, S., Büttner, T., Temme, C., Ruben, M., Görls, H., Walther, D., Duati, M., Fanni, S., & Vos, J. G. (2000). A bibenzimidazole-containing ruthenium(II) complex acting as a cation-driven molecular switch. Inorganic chemistry, 39(7), 1621-4. https://doi.org/10.1021/ic991225h
Rau, S, et al. "A bibenzimidazole-containing ruthenium(II) complex acting as a cation-driven molecular switch." Inorganic chemistry vol. 39,7 (2000): 1621-4. doi: https://doi.org/10.1021/ic991225h
Rau S, Büttner T, Temme C, Ruben M, Görls H, Walther D, Duati M, Fanni S, Vos JG. A bibenzimidazole-containing ruthenium(II) complex acting as a cation-driven molecular switch. Inorg Chem. 2000 Apr 03;39(7):1621-4. doi: 10.1021/ic991225h. PMID: 12526478.
Copy Download .nbib Format: NLM
Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer.

Breast care (Basel, Switzerland)

Janni W, von Minckwitz G, Möbus V, Nitz U.
PMID: 20824004
Breast Care (Basel). 2008;3:17-20. doi: 10.1159/000119747. Epub 2008 Apr 26.

No abstract available.

Cite
Janni W, von Minckwitz G, Möbus V, et al. Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast Care (Basel). 2008;3:17-20doi: 10.1159/000119747.
Janni, W., von Minckwitz, G., Möbus, V., & Nitz, U. (2008). Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast care (Basel, Switzerland), 317-20. https://doi.org/10.1159/000119747
Janni, Wolfgang, et al. "Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer." Breast care (Basel, Switzerland) vol. 3 (2008): 17-20. doi: https://doi.org/10.1159/000119747
Janni W, von Minckwitz G, Möbus V, Nitz U. Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast Care (Basel). 2008;3:17-20. doi: 10.1159/000119747. Epub 2008 Apr 26. PMID: 20824004; PMCID: PMC2930992.
Copy Download .nbib Format: NLM
Risk of incisional recurrence after midface and anterior skull base surgery in sinonasal malignancies.

Skull base : official journal of North American Skull Base Society ... [et al.]

Moore MG, Lin DT, Deschler DG, Wang JJ, Chan AW.
PMID: 22451807
Skull Base. 2011 Mar;21(2):87-92. doi: 10.1055/s-0030-1266762.

We sought to determine the risk of tumor incisional recurrence in patients receiving surgery and postoperative radiation therapy for locally advanced sinonasal malignancies. Medical records for 70 patients newly diagnosed with nonmetastatic American Joint Committee on Cancer stage II...

Cite
Moore MG, Lin DT, Deschler DG, et al. Risk of incisional recurrence after midface and anterior skull base surgery in sinonasal malignancies. Skull Base. 2011;21(2):87-92doi: 10.1055/s-0030-1266762.
Moore, M. G., Lin, D. T., Deschler, D. G., Wang, J. J., & Chan, A. W. (2011). Risk of incisional recurrence after midface and anterior skull base surgery in sinonasal malignancies. Skull base : official journal of North American Skull Base Society ... [et al.], 21(2), 87-92. https://doi.org/10.1055/s-0030-1266762
Moore, Michael G, et al. "Risk of incisional recurrence after midface and anterior skull base surgery in sinonasal malignancies." Skull base : official journal of North American Skull Base Society ... [et al.] vol. 21,2 (2011): 87-92. doi: https://doi.org/10.1055/s-0030-1266762
Moore MG, Lin DT, Deschler DG, Wang JJ, Chan AW. Risk of incisional recurrence after midface and anterior skull base surgery in sinonasal malignancies. Skull Base. 2011 Mar;21(2):87-92. doi: 10.1055/s-0030-1266762. PMID: 22451807; PMCID: PMC3312592.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 355 entries